Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. The company's management will take part in a fireside chat on Friday, September 6th at 9:20 a.m. Pacific Time / 12:20 p.m. Eastern Time.
Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment. Interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the company's website at www.adaptivebiotech.com.
Positive
- None.
Negative
- None.
News Market Reaction – ADPT
In the trading session that priced this news, ADPT gained 10.45%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Friday, September 6th at 9:20 a.m. Pacific Time / 12:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
